Vanguard Capital Management
CGEM icon

Vanguard Capital Management’s Cullinan Oncology CGEM Stock Holding History

Vanguard Capital Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.6M Buy
2,614,066
+131,032
+5% +$1.95M ﹤0.01% 1976
2026
Q1 		$35.3M Buy
+2,483,034
New +$31.9M ﹤0.01% 2044

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management's CGEM Position: Q2 2026 in Review

Vanguard Capital Management increased its Cullinan Oncology (CGEM) stake by 5.3% in Q2 2026, buying an estimated $1.95M and bringing the position to 2,614,066 shares worth $47.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1976.

Vanguard Capital Management first reported a position in CGEM in Q1 2026 and has held it in 2 quarters since. 182 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Vanguard Capital Management held 2,614,066 shares of Cullinan Oncology worth $47.6M as of Q2 2026.
  • Vanguard Capital Management bought 131,032 Cullinan Oncology shares in Q2 2026, an estimated $1.95M.
  • Cullinan Oncology made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1976 holding.
  • Vanguard Capital Management first reported a position in Cullinan Oncology in Q1 2026 and has held it in 2 quarters since.
  • 182 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.